Langland, announces the appointment of Alison Ferrucci to its Board. Alison joined Langland as an Account Executive in 2001 and took responsibility for many of the agency’s accounts including Levitra / Sorted in 10 (Bayer / GSK), Crestor (AstraZeneca), Bonefos (Bayer), Nexavar (Bayer), and Synagis (Abbott Laboratories). Alison rose quickly through the agency ranks gaining promotion to Client Services Director in June 2009. In this role she led the agency’s Ethical account handling team, building the reputation of the agency by driving excellence in client service. After taking a year’s maternity leave, Alison returned to Langland in 2013 as Strategic Delivery Director, a newly created role with a strong focus on business process excellence and commercial delivery.
Along with the appointment of Alison Ferrucci to the Langland Board, the agency has also made two other changes to its Board. Kate Spencer moves to Managing Partner from Global Business Director and Andrew Spurgeon moves to become Executive Creative Director.
Commenting on the appointment and changes, Philip Chin, Langland’s Chief Executive said: “Alison’s leadership qualities, her knowledge of our clients and her understanding of the changing business environment which we operate within, means she is ideally placed to strengthen and contribute to the Langland Board. Kate and Andrew’s moves acknowledge the contribution that both have made to the agency in recent years and also paves the way for future organisational development, as we expand in scale and geographical reach to meet the needs of our clients.”